FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979393286> ?p ?o ?g. }

• W2979393286 endingPage "20190380" @default.
• W2979393286 startingPage "20190380" @default.
• W2979393286 abstract "To evaluate the therapeutic response, progression free survival (PFS), overall survival (OS) and clinical toxicity of 177Lu-PSMA-617 PSMA targeted radioligand therapy (PRLT) in the setting of heavily pre-treated metastatic castrate-resistant prostate cancer (mCPRC) patients and also examine the association of prognostic variables with therapeutic outcome in such patient cohort.We examined the medical records of mCRPC patients who had undergone 177Lu-PSMA-617 PRLT from March 2017 to February 2019 in our institute. Patients receiving equal to or more than two cycles were included and analyzed in this retroprospective study.The 68Ga-PSMA-11 PET-CT and 18-fludeoxyglucose positron emission tomography (18FDG PET)-CT scan findings, serum prostate-specific antigen (PSA) change, health-related quality of life (HRQoL) scales (Eastern Cooperative Oncology Group/Karnofsky score) and Gleason score were assessed for their implications on the outcome of therapy. The treatment response was evaluated under three categories: (a) symptomatic (b) biochemical and (c) imaging response.The PFS and OS following first PRLT were determined and the association of various variables with PSA doubling time (DT) and FDG uptake in the lesions were analyzed. Toxicity assessment was undertaken objectively by National Cancer Institute-Common Terminology Criteria for Adverse Events scale v. 5.0 for haematological and nephrotoxicity, and salivary gland toxicity assessed by xerostomia inventory score.A total of 40 mCRPC patients (age range: 46-84 years; median 63 years), who had undergone 177Lu-PSMA-617 PRLT, of at least two cycles was identified and selected for the analysis. FDG uptake was noted in 87.5% of patients (n = 35). Out of 40 cases, 21 were responders (CR, PR and SD) and 19 were non-responders (PD) on symptomatic and biochemical scales while on molecular imaging response, 16 (43%) were responders and remaining 21 (57%) were non-responders. Lesion-wise, 68Ga-PSMA-11 avid metastatic nodal disease responded well with 177Lu PSMA-617 PRLT, as compared to hepatic and skeletal lesions. The median OS and PFS was 12 and 7 months respectively following first PRLT. Patients with negative serum PSA-DT demonstrated superior 1 year PFS as compared to those with positive serum PSA-DT (52.5 vs 47.5%) (p = 0.029). Patients receiving greater than two cycles PRLT demonstrated a higher negative PSA-DT as compared to those receiving two cycles (p-value = 0.03). Grade 1 xerostomia was observed in two patients (5%) (mean xerostomia score of 23), haematotoxicity in seven patients [Grade I (n = 2, 5%) and Grade II (n = 5, 14%)].177Lu-PSMA-617 PRLT was well-tolerated and able to produce disease control with good symptomatic and biochemical responses in the context of heavily pre-treated mCRPC with progressive disease, with low toxicity profile. Evident association of high FDG uptake was observed with aggressive disease biology coupled with increasing Gleason score and poorer 12 months PFS. Negative PSA-DT following therapy demonstrated longer PFS. The results demonstrate important future role of 177Lu-PSMA-617 PRLT in the treatment of mCRPC.The present work explored in a large teriary cancer care setting, the efficacy of 177Lu-PSMA-617 PRLT, in an aggressive and unselected subset of mCRPC. The response and outcome was correlated with a number of prognostic variables, including molecular imaging findings (FDG uptake in the metastatic lesions), PSA DT and Gleason score." @default.
• W2979393286 created "2019-10-18" @default.
• W2979393286 creator A5001390430 @default.
• W2979393286 creator A5003412464 @default.
• W2979393286 creator A5007636610 @default.
• W2979393286 creator A5022053889 @default.
• W2979393286 creator A5051806826 @default.
• W2979393286 creator A5054315303 @default.
• W2979393286 creator A5082030725 @default.
• W2979393286 creator A5088525257 @default.
• W2979393286 date "2019-12-01" @default.
• W2979393286 modified "2023-09-24" @default.
• W2979393286 title "Therapeutic efficacy, prognostic variables and clinical outcome of ¹⁷⁷Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort" @default.
• W2979393286 cites W1925346801 @default.
• W2979393286 cites W1942863632 @default.
• W2979393286 cites W1979570009 @default.
• W2979393286 cites W2031633106 @default.
• W2979393286 cites W2038995735 @default.
• W2979393286 cites W2067514492 @default.
• W2979393286 cites W2081110856 @default.
• W2979393286 cites W2089057473 @default.
• W2979393286 cites W2099017226 @default.
• W2979393286 cites W2103904089 @default.
• W2979393286 cites W2110788033 @default.
• W2979393286 cites W2113556350 @default.
• W2979393286 cites W2123526148 @default.
• W2979393286 cites W2123833251 @default.
• W2979393286 cites W2124807421 @default.
• W2979393286 cites W2127208148 @default.
• W2979393286 cites W2134437701 @default.
• W2979393286 cites W2139860898 @default.
• W2979393286 cites W2153679149 @default.
• W2979393286 cites W2302508993 @default.
• W2979393286 cites W2303817381 @default.
• W2979393286 cites W2397136240 @default.
• W2979393286 cites W2513308461 @default.
• W2979393286 cites W2518199070 @default.
• W2979393286 cites W2523333323 @default.
• W2979393286 cites W2525124727 @default.
• W2979393286 cites W2592847372 @default.
• W2979393286 cites W2799931007 @default.
• W2979393286 cites W2914833937 @default.
• W2979393286 cites W4244205613 @default.
• W2979393286 cites W4328001230 @default.
• W2979393286 cites W73427462 @default.
• W2979393286 doi "https://doi.org/10.1259/bjr.20190380" @default.
• W2979393286 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6913363" @default.
• W2979393286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31600089" @default.
• W2979393286 hasPublicationYear "2019" @default.
• W2979393286 type Work @default.
• W2979393286 sameAs 2979393286 @default.
• W2979393286 citedByCount "41" @default.
• W2979393286 countsByYear W29793932862019 @default.
• W2979393286 countsByYear W29793932862020 @default.
• W2979393286 countsByYear W29793932862021 @default.
• W2979393286 countsByYear W29793932862022 @default.
• W2979393286 countsByYear W29793932862023 @default.
• W2979393286 crossrefType "journal-article" @default.
• W2979393286 hasAuthorship W2979393286A5001390430 @default.
• W2979393286 hasAuthorship W2979393286A5003412464 @default.
• W2979393286 hasAuthorship W2979393286A5007636610 @default.
• W2979393286 hasAuthorship W2979393286A5022053889 @default.
• W2979393286 hasAuthorship W2979393286A5051806826 @default.
• W2979393286 hasAuthorship W2979393286A5054315303 @default.
• W2979393286 hasAuthorship W2979393286A5082030725 @default.
• W2979393286 hasAuthorship W2979393286A5088525257 @default.
• W2979393286 hasBestOaLocation W29793932862 @default.
• W2979393286 hasConcept C121608353 @default.
• W2979393286 hasConcept C126322002 @default.
• W2979393286 hasConcept C143998085 @default.
• W2979393286 hasConcept C197934379 @default.
• W2979393286 hasConcept C2775842073 @default.
• W2979393286 hasConcept C2777793932 @default.
• W2979393286 hasConcept C2780192828 @default.
• W2979393286 hasConcept C29730261 @default.
• W2979393286 hasConcept C2989005 @default.
• W2979393286 hasConcept C2993559085 @default.
• W2979393286 hasConcept C71924100 @default.
• W2979393286 hasConcept C72563966 @default.
• W2979393286 hasConceptScore W2979393286C121608353 @default.
• W2979393286 hasConceptScore W2979393286C126322002 @default.
• W2979393286 hasConceptScore W2979393286C143998085 @default.
• W2979393286 hasConceptScore W2979393286C197934379 @default.
• W2979393286 hasConceptScore W2979393286C2775842073 @default.
• W2979393286 hasConceptScore W2979393286C2777793932 @default.
• W2979393286 hasConceptScore W2979393286C2780192828 @default.
• W2979393286 hasConceptScore W2979393286C29730261 @default.
• W2979393286 hasConceptScore W2979393286C2989005 @default.
• W2979393286 hasConceptScore W2979393286C2993559085 @default.
• W2979393286 hasConceptScore W2979393286C71924100 @default.
• W2979393286 hasConceptScore W2979393286C72563966 @default.
• W2979393286 hasIssue "1104" @default.
• W2979393286 hasLocation W29793932861 @default.
• W2979393286 hasLocation W29793932862 @default.
• W2979393286 hasLocation W29793932863 @default.
• W2979393286 hasOpenAccess W2979393286 @default.
• W2979393286 hasPrimaryLocation W29793932861 @default.
• W2979393286 hasRelatedWork W1135596034 @default.

• next